When making a decision, health care providers must implement the best evidence proven to produce a quality-care outcome. Drugs that are not proven to use in a particular group of people may also increase the risk of liability for the practitioner and other stakeholders. References American Academy of Pediatrics. (2014). Off-Label Use of Drugs in Children. 133(3), p 563- 567; doi: 10.1542/peds.2013-4060. Retrieved from:
Arcangelo, V. P., Peterson, A. M., Wilbur, V. & Reinhold, J. A. (Eds.). (2017). Pharmacotherapeutics for advanced practice: A practical approach (4th ed.). Ambler, PA: Lippincott Williams & Wilkins. Corny, J., Lebel, D., Bailey, B., & Bussières, J. F. (2015). Unlicensed and Off-Label Drug Use in Children Before and After Pediatric Governmental Initiatives. The journal of pediatric pharmacology and therapeutics: JPPT: the official journal of PPAG, 20(4), 316-28.Frattarelli, D. A., Galinkin, J. L., Green, T. P., Johnson, T. D., Neville, K. A., Paul, I. M., & Van Den Anker, J. N. (2014). Off-label use of drugs in children. Pediatrics, 133(3), 563-567. doi:10.1542/peds.2013-4060 U.S. Department of Health and Human Services. (2016). Drug research and children. Retrieved from Wimmer, S., Neubert, A., & Rascher, W. (2015). The Safety of Drug Therapy in Children.
You've reached the end of your free preview.
Want to read all 4 pages?